Comparison tool
Wolverine Stack vs Glow Protocol side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Wolverine Stack | Glow Protocol |
|---|---|---|
| Category | Peptide Blend | Peptide Blend |
| Also known as | Wolverine Blend, BPC-157/TB-500 Stack, Healing Stack | Glow Stack, Glow Blend, Skin Rejuvenation Stack |
| FDA approved | No | No |
| Clinical status | Preclinical Research (Components)
| Preclinical Research (Components)
|
| What to expect | Injury recovery, healing optimization, joint repair | Skin rejuvenation, anti-aging, collagen production |
| How it works | Wolverine Stack is presented as a two-component repair-focused blend rather than a single molecule. The source attributes BPC-157 activity to preclinical findings involving angiogenesis and growth-factor or nitric-oxide signaling in damaged tissue. TB-500 is described through its relationship to the actin-binding region of thymosin beta-4, with proposed effects on cell migration, actin regulation, and recruitment of cells involved in repair. The source explicitly limits these ideas to animal, cell, or other preclinical evidence rather than confirmed human effects for the stack. | Glow Protocol is described as a three-component peptide blend. GHK-Cu is the copper-binding tripeptide in the stack and is linked in the source to collagen, elastin, glycosaminoglycan production, matrix metalloproteinase modulation, and angiogenesis signals from cell and animal evidence. BPC-157 is included for proposed pro-healing and anti-inflammatory activity tied to angiogenesis and growth-factor signaling in rodent studies. TB-500 is described as an actin-binding thymosin beta-4 fragment included for cell migration and tissue-remodeling hypotheses. The source explicitly frames the combined mechanism as plausible extrapolation rather than proof that the injectable blend works as a unified product. |
| Typical dosing | 250-500 mcg of each peptide daily · Once or twice daily · Subcutaneous injection | Standard vial dosing per protocol · Once daily |
| Research dosing | BPC-157 10mg + TB-500 10mg per vial · 4-12 weeks depending on injury · Subcutaneous injection | 5:1:1 ratio GHK-Cu:TB-500:BPC-157 · 8-12 weeks for visible results · Subcutaneous injection |
| Typical duration | 4-12 weeks depending on injury | 8-12 weeks for visible results |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Timing | Morning or post-workout With or without food | Evening With or without food |
| Evidence level | Preclinical | Preclinical |
| Possible side effects |
+1 more
|
+1 more
|
| Research summary | The source states that Wolverine Stack itself has no human randomized controlled trial evidence as a combination. It also reports no completed phase 2 or phase 3 tissue-repair trials for BPC-157 or TB-500 individually. The cited evidence base is described as mostly rodent, animal, and cell-model research: BPC-157 is associated in those models with tendon, ligament, muscle, and gut-healing findings, while TB-500 or thymosin beta-4 biology is associated with wound-healing and cell-migration models. The source notes that full thymosin beta-4 has reached human trials in areas such as pressure ulcers and dry eye, but distinguishes that from the TB-500 fragment used in stack discussions. | The source distinguishes the evidence for the ingredients. GHK-Cu is described as having the strongest human support, but specifically from topical cosmetic studies rather than injectable Glow Protocol use; reported topical outcomes include reduced wrinkle depth and better skin density and firmness across 8 to 12 weeks. A gene-profiling analysis is also cited as finding broad GHK associations with wound-repair and inflammation-related human genes, but the source characterizes that as computational rather than direct clinical evidence. BPC-157 and TB-500 are described as remaining in the animal-data category without completed human efficacy trials. The source further states that the injected GLOW blend has no published trial of its own, so topical GHK-Cu results should not be assumed to apply to the injectable three-peptide blend. It also flags injection of copper peptides as a risk area not addressed by topical studies. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.